Sample CMS 1450 (UB-04) Form:

Sample CMS 1450 (UB-04) Form:
How to bill for a drug with an assigned HCPCS for Medicare hospital
outpatient departments. Check with your local payers for
appropriate coding requirements.
__
__
__
4
3a PAT.
CNTL #
b. MED.
REC. #
2
__
1
6
5 FED. TAX NO.
8 PATIENT NAME
9 PATIENT ADDRESS
a
10 BIRTHDATE
31
11 SEX
OCCURRENCE
12
32
DATE
a
c
ADMISSION
13 HR 14 TYPE 15 SRC 16 DHR 17 STAT
33
OCCURRENCE
DATE
CODE
OCCURRENCE
DATE
DATE
Optional CODE
- Column
43: CODE
Kyprolis® (carfilzomib) for Injection
18
7
STATEMENT COVERS PERIOD
FROM
THROUGH
b
b
TYPE
OF BILL
19
20
34
OCCURRENCE
CODE
DATE
35
CODE
38
Indicate name of medication administered.
Example: Kyprolis (carfilzomib) for Injection
CONDITION CODES
24
22
23
21
a
25
26
36
CODE
OCCURRENCE SPAN
FROM
THROUGH
39
CODE
40
CODE
VALUE CODES
AMOUNT
27
d
28
e
29 ACDT 30
STATE
37
OCCURRENCE SPAN
FROM
THROUGH
VALUE CODES
AMOUNT
b
Column 47: Total Charges
41
CODE
VALUE CODES
AMOUNT
Indicate the facility’s actual charges
for products and procedures.
c
d
42 REV. CD.
44 HCPCS / RATE / HIPPS CODE
43 DESCRIPTION
45 SERV. DATE
46 SERV. UNITS
47 TOTAL CHARGES
48 NON-COVERED CHARGES
49
1
1
2
2
3
3
4
4
Column 46: Service Units
5
5
6
6
Report the appropriate unit
of
7
service. Carfilzomib is billed
on a
8
“per milligram” basis.
9
Example: One vial of Kyprolis
10
is equal to 60 units of J9047
11
Column 42: Revenue Code(s)
7
8
Enter appropriate
product/procedure
9
revenue codes.
10
Product11Revenue Codes:
12 0636 “Drugs that require
Example:
13
detail coding”
14
Please note:
Revenue code requirements
may vary15by payer. Check with payer to
16
determine
the appropriate revenue code
for billing.17
18
Procedure
Revenue Codes:
19
Enter appropriate procedure revenue code.
20
Use the most appropriate revenue code for
21
the service performed.
22
Example:
0335 “Radiology-Therapeutic23
PAGE
OF
Chemotherapy-IV”
50 PAYER NAME
Column 44: Product/Procedure Code(s)
Product Code:
Indicate the appropriate HCPCS code for the
drug administered.
Example: J9047 Injection, carfilzomib, 1 mg
Procedure Code:
Example: 96409 Chemotherapy administration;
intravenous, push technique, single or initial
substance/drug
12
13
14
15
16
17
18
19
20
21
22
TOTALS
CREATION DATE
52 REL.
INFO
51 HEALTH PLAN ID
53 ASG.
BEN.
23
55 EST. AMOUNT DUE
54 PRIOR PAYMENTS
56 NPI
A
57
A
B
OTHER
B
PRV ID
C
C
58 INSURED’S NAME
62 INSURANCE GROUP NO.
61 GROUP NAME
59 P. REL 60 INSURED’S UNIQUE ID
A
A
B
B
C
C
63 TREATMENT AUTHORIZATION CODES
Box 67: Diagnosis Code
A
B
C
66
DX
67
I
A
Enter appropriate ICD-9-CM
diagnosis code.
A Example: B
C
D
203.02 Multiple myeloma J
K
L
M71 PPS
70 PATIENT
in relapse
69 ADMIT
DX
REASON DX
PRINCIPAL PROCEDURE
a.
74
CODE
DATE
a
b
OTHER PROCEDURE
CODE
DATE
b.
OTHER PROCEDURE
CODE
DATE
e.
65 EMPLOYER NAME
64 DOCUMENT CONTROL NUMBER
c
CODE
OTHER PROCEDURE
CODE
DATE
B
E
N
75
72
ECI
F
O
76 ATTENDING
G
P
NPI
LAST
c.
OTHER PROCEDURE
CODE
DATE
d.
OTHER PROCEDURE
CODE
DATE
77 OPERATING
81CC
a
UB-04 CMS-1450
APPROVED OMB NO.
78 OTHER
b
LAST
c
79 OTHER
d
LAST
C
68
73
QUAL
FIRST
NPI
LAST
80 REMARKS
H
Q
QUAL
FIRST
NPI
QUAL
FIRST
NPI
QUAL
FIRST
THE CERTIFICATIONS ON THE REVERSE APPLY TO THIS BILL AND ARE MADE A PART HEREOF.
NUBC
™
National Uniform
Billing Committee
LIC9213257
For reimbursement assistance and personalized patient support services, contact
Onyx Pharmaceuticals 360™ at 1-855-ONYX-360 (1-855-669-9360).
Please note: This document is an abbreviated reference and the information described herein is subject to continual change and interpretation. Providers must assure
themselves that this information is accurate and applicable to the claim being filed and should contact the insurer to determine the appropriate codes for the services
provided. Onyx Pharmaceuticals, Inc. does not guarantee that use of any code(s) will assure coverage or payment at any level. The information presented is for
informational purposes only and is not intended to provide reimbursement or legal advice. The appropriateness of filing any particular claim is and remains the
responsibility of the provider based on the provider’s own judgment.
Please see Important Safety Information and full Prescribing Information.
Indication and Important Safety Information
INDICATION
Kyprolis® (carfilzomib) for Injection is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior
therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days
of completion of the last therapy. Approval is based on response rate. Clinical benefit, such as improvement in survival or symptoms,
has not been verified.
CONTRAINDICATIONS
None.
WARNINGS AND PRECAUTIONS
The safety of KYPROLIS was evaluated in clinical studies of 526 patients with relapsed and/or refractory multiple myeloma.
Cardiac Arrest, Congestive Heart Failure, Myocardial Ischemia: Death due to cardiac arrest has occurred within a day of
KYPROLIS administration. New onset or worsening of pre-existing congestive heart failure with decreased left ventricular function
or myocardial ischemia have occurred following administration of KYPROLIS. Cardiac failure events (e.g., cardiac failure congestive,
pulmonary edema, ejection fraction decreased) were reported in 7% of patients. Monitor for cardiac complications and manage
promptly. Withhold KYPROLIS for Grade 3 or 4 cardiac events until recovery and consider whether to restart KYPROLIS based on a
benefit/risk assessment. Patients with New York Heart Association Class III and IV heart failure, myocardial infarction in the preceding
6 months, and conduction abnormalities uncontrolled by medications may be at greater risk for cardiac complications.
Pulmonary Hypertension: Pulmonary arterial hypertension (PAH) was reported in 2% of patients treated with KYPROLIS and was
Grade 3 or greater in less than 1% of patients. Evaluate with cardiac imaging and/or other tests as indicated. Withhold KYPROLIS
for pulmonary hypertension until resolved or returned to baseline and consider whether to restart KYPROLIS based on a
benefit/risk assessment.
Pulmonary Complications: Dyspnea was reported in 35% of patients enrolled in clinical trials. Grade 3 dyspnea occurred in 5%;
no Grade 4 events, and 1 death (Grade 5) was reported. Monitor and manage dyspnea immediately; interrupt KYPROLIS until
symptoms have resolved or returned to baseline.
Infusion Reactions: Infusion reactions were characterized by a spectrum of systemic symptoms including fever, chills, arthralgia,
myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or
angina. These reactions can occur immediately following infusion or up to 24 hours after administration of KYPROLIS. Administer
dexamethasone prior to KYPROLIS to reduce the incidence and severity of reactions. Inform patients of the risk and symptoms, and
to contact physician if symptoms of an infusion reaction occur.
Tumor Lysis Syndrome: Tumor lysis syndrome (TLS) occurred following KYPROLIS administration in < 1% of patients. Patients with
multiple myeloma and a high tumor burden should be considered to be at greater risk for TLS. Prior to receiving KYPROLIS, ensure that
patients are well hydrated. Monitor for evidence of TLS during treatment, and manage promptly. Interrupt KYPROLIS until TLS is resolved.
Thrombocytopenia: KYPROLIS causes thrombocytopenia with platelet nadirs occurring around Day 8 of each 28-day cycle
and recovery to baseline by the start of the next 28-day cycle. In patients with multiple myeloma, 36% of patients experienced
thrombocytopenia, including Grade 4 in 10%. Thrombocytopenia following KYPROLIS administration resulted in a dose reduction
in 1% of patients and discontinuation of treatment with KYPROLIS in < 1% of patients. Monitor platelet counts frequently during
treatment with KYPROLIS. Reduce or interrupt dose as clinically indicated.
Hepatic Toxicity and Hepatic Failure: Cases of hepatic failure, including fatal cases, have been reported (< 1%). KYPROLIS can
cause elevations of serum transaminases and bilirubin. Withhold KYPROLIS in patients experiencing Grade 3 or greater elevations
of transaminases, bilirubin, or other liver enzyme abnormalities until resolved or returned to baseline. After resolution, consider if
restarting KYPROLIS is appropriate. Monitor liver enzymes frequently.
Embryo-fetal Toxicity: KYPROLIS can cause fetal harm when administered to a pregnant woman based on its mechanism of action
and findings in animals. There are no adequate and well-controlled studies in pregnant women using KYPROLIS. Carfilzomib caused
embryo-fetal toxicity in pregnant rabbits at doses that were lower than in patients receiving the recommended dose. Females of
reproductive potential should be advised to avoid becoming pregnant while being treated with KYPROLIS.
ADVERSE REACTIONS
Serious adverse reactions were reported in 45% of patients. The most common serious adverse reactions were pneumonia (10%),
acute renal failure (4%), pyrexia (3%), and congestive heart failure (3%). Adverse reactions leading to discontinuation of KYPROLIS
occurred in 15% of patients and included congestive heart failure (2%), cardiac arrest, dyspnea, increased blood creatinine, and
acute renal failure (1% each).
The most common adverse reactions (incidence ≥ 30%) were fatigue (56%), anemia (47%), nausea (45%), thrombocytopenia (36%),
dyspnea (35%), diarrhea (33%), and pyrexia (30%).
USE IN SPECIFIC POPULATIONS
Since dialysis clearance of KYPROLIS concentrations has not been studied, the drug should be administered after the dialysis procedure.
More Information: For more information about KYPROLIS, visit www.KYPROLIS.com/hcp.
Onyx, Onyx Pharmaceuticals, Onyx Pharmaceuticals logo, Onyx Pharmaceuticals 360, Kyprolis and Kyprolis logo are all
trademarks of Onyx Pharmaceuticals, Inc.
©2013 Onyx Pharmaceuticals, Inc., South San Francisco, CA
Please see full Prescribing Information.
1112-CARF-447bR1
December 2013
Printed in USA